2023 Society of Urologic Oncology (SUO) Annual Meeting
SUO 2023 Prostate Cancer
- SUO 2023: Joseph A. Smith, Jr. Mentorship Award Lecture: Take Inventory, Embrace Failure, Move Forward, and Be Grateful
- SUO 2023: Decipher® Genomic Classifier on Initial Prostate Biopsy is Associated with Gleason Score Upgrading on Final Radical Prostatectomy Pathology
- SUO 2023: Factors Associated with PSMA Positivity at Low PSA After Radical Prostatectomy
- SUO 2023: Decipher® Genomic Classifier Score on Initial Biopsy is Associated with Progression from Active Surveillance to Treatment in Prostate Cancer
- SUO 2023: Grade and Volume Progression and Its Association with the Decipher® Genomic Classifier Using Patients Enrolled in a Prospective Active Surveillance Protocol
SUO 2023 Bladder Cancer
- SUO 2023: Optimizing Care for Women: Gynecologic Considerations for the Urologic Oncologist
- SUO 2023: Long-term Outcomes of Bladder-Sparing Therapy Compared to Upfront Radical Cystectomy in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in an International Cohort
- SUO 2023: Primary Chemoablation for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer: The ENVISION Trial
- SUO 2023: First Results from BOND-003, a Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec Monotherapy for Patients with High-Risk BCG Unresponsive NMIBC
- SUO 2023: Treatment of Low-grade, Intermediate-risk Non-muscle Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor (TURBT) compared to TURBT Monotherapy: The Phase 3 ATLAS Trial
SUO 2023 Penile, Urethral, Testicular, and Adrenal Cancers
SUO 2023 Upper Tract Urothelial Carcinoma
- SUO 2023: Systemic Therapy: Choosing Among Neoadjuvant/adjuvant Approaches for Upper Tract Urothelial Carcinoma
- SUO 2023: Trials in Upper Tract Urothelial Carcinoma and Unmet Needs
- SUO 2023: Defining the Biology of Upper Tract Urothelial Carcinoma and How This Shapes Therapy
- SUO 2023: The Role of Biomarkers for UTUC Risk Stratification
- SUO 2023: UTUC: Chemoablation and Renal Preservation is the Future
SUO 2023 Press Releases
- SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy
- New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
- UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology